DSKYF - AbbVie-Immunogen deal lifts ADC-focused biotechs
2023-11-30 12:17:22 ET
More on AbbVie, ImmunoGen, etc.
- AbbVie: Get Ready For More Painful Downside
- AbbVie: Collect Growing Passive Income From This Dividend Aristocrat (Rating Upgrade)
- Buy The Dip In AbbVie? Nope, Not This Time
- Biggest stock movers today: Snap, ImmunoGen, Snowflake, Salesforce and more
- AbbVie to acquire cancer drugmaker ImmunoGen for $10B cash (update)
For further details see:
AbbVie-Immunogen deal lifts ADC-focused biotechs